Integer Holdings Corp

ITGR

Equity

ISIN US45826H1095 / Valor 33080752

New York Stock Exchange, Inc (2024-12-24)

USD 134.75+0.80%

Integer Holdings Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Integer Holdings Corp is a leading medical device technology company that designs and manufactures a wide range of products, including catheters, guidewires, implantable ports, neuromodulation devices, and pacemaker batteries. With expertise in medical device development and battery design, Integer serves various markets, providing innovative solutions to medical device OEMs. The company's brands, such as Greatbatch Medical® and Lake Region Medical®, have a strong reputation for delivering high-quality products. With a history of industry-changing innovations and manufacturing excellence, Integer continues to be a trusted partner in the medical device industry, offering expertise in cardiac rhythm, cardio and vascular health, neuromodulation, and portable power solutions.

Summarized from source with an LLMView SourceSector: Finance

Revenue Growth

Integer Holdings Corp reported a 9% increase in sales for Q2 2024, reaching $436 million. This growth, although slightly below the analyst estimate of $437.02 million, demonstrates the company's resilience and ability to expand its market presence.

Net Income and EPS

For the second quarter of 2024, Integer Holdings Corp's GAAP net income increased by 30% to $31 million. The GAAP diluted EPS was $0.88, up by $0.17 per share from the previous year, surpassing the analyst estimate of $0.85.

Operating Income and EBITDA

Integer Holdings Corp's GAAP operating income for Q2 2024 increased by 33% to $55 million. Additionally, the company's adjusted EBITDA saw a 19% rise, reaching $91 million, reflecting strong operational efficiency and profitability.

Debt and Cash Flow

As of the end of Q2 2024, Integer Holdings Corp's total debt increased by $159 million to $1.119 billion, primarily due to the acquisition of Pulse Technologies. The company's cash and cash equivalents stood at $34.1 million, up from $23.7 million at the end of 2023.

Segment Performance

In Q2 2024, Integer Holdings Corp saw a 11% increase in Cardio & Vascular sales, a 9% rise in Cardiac Rhythm Management & Neuromodulation sales, and a 4% growth in Advanced Surgical, Orthopedics & Portable Medical sales. However, Electrochem sales decreased, returning to a normalized run-rate after previously higher sales from the supply chain recovery.

Summarized from source with an LLMView Source

Key figures

35.6%1Y

57.1%3Y

65.2%5Y

Performance

28.0%1Y

33.5%3Y

40.5%5Y

Volatility